Concord Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹312 Cr +26.3% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
CB

Concord Biotech Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Concord Biotech Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹278Cr
+13.9% YoY
+12.6% QoQ
Net profit
₹68Cr
−8.1% YoY
+7.9% QoQ
Margin
37%
−3 pp YoY
0 pp QoQ
Price₹1,571
Market cap₹14.5K Cr
P/E51.0

The short version

FY '26 growth expected below historical averages due to first-half challenges; optimistic for Q4 improvement. FY '26 growth expected below historical averages due to H1 challenges but Q3 & Q4 show improving momentum.

From Concord Biotech Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • FY '26 growth expected below historical averages due to first-half challenges; optimistic for Q4 improvement.
  • Medium-term growth drivers include:
  • Injectables contributing around 6% growth over the next 3-5 years.
  • CDMO segment growth due to global shift favoring India.
  • Combined baseline growth (API and formulations) around 18%, with injectables and CDMO potentially raising CAGR to ~25% over time.
  • Expansion plans involve new product launches, increasing market share in anti-infectives, antifungal, and oncology segments.
  • Non-immunosuppressant products expected to gain market share gradually, similar to immunosuppressants, focusing on complex, niche products with limited competition.
  • Moderate volume-led growth in API business; pricing remains stable, with limited discounts.

2 more points from Concord Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Concord Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Additional capex beyond maintenance is being incurred for newer projects linked to customer opportunities and growth, contributing to a blended capex of INR 100-150 crores annually.
  • The company is investing in commercialization of new injectable facilities and subsidiaries in the U.S. market, with the injectable facility having a peak revenue potential of approximately INR 600 crores.
  • Concord Lifegen Limited, a wholly owned subsidiary, was incorporated to strengthen marketing, sales, and distribution in India.

2 more points from Concord Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Concord Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • It mentions increased engagement and advanced discussions around second source supply opportunities post-clarity on U.S. tariffs, indicating a growing pipeline of potential orders.
  • Discussions are underway with both existing customers and new innovator/generic players, with expectations of commercializing at least one new project in the near term.
  • The company is optimistic about growth momentum entering Q4 FY '26 and expects improved performance driven by new product launches and CDMO partnerships.
  • There is ongoing evaluation of both organic and inorganic options for utilizing cash flow to capture future growth opportunities.

Concord Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Concord Biotech Ltd Q3 FY26 results — key figures

Concord Biotech Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue278244+13.9%247+12.6%
Operating profit (EBITDA)10298+4.1%91+12.1%
Operating margin37%40%-3 pp37%0 pp
Profit before tax9099-9.1%86+4.7%
Net profit (PAT)6874-8.1%63+7.9%
EPS (₹)3.243.54-8.5%3.01+7.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹312 Cr, net profit ₹76 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Concord Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Concord Biotech Ltd Q3 FY26 results?

FY '26 growth expected below historical averages due to first-half challenges; optimistic for Q4 improvement. FY '26 growth expected below historical averages due to H1 challenges but Q3 & Q4 show improving momentum.

What is Concord Biotech Ltd share price analysis?

Concord Biotech Ltd currently shows a neutral. The stock trades at a P/E of 51.0 with a market cap of ₹14,489 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Concord Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.